Neuroendocrine neoplasm
Therapeutic area
Endocrinology
Rare disease
Yes
- Definition
- Endocrine tumors, also referred to as neuroendocrine tumors (NETs), are defined by a common phenotype which is characterized by the expression of general markers (neuron specific enolase, chromogranin, synaptophysin) and hormone secretion products. These tumors may be localized in any part of the body and are generally discovered in non-specific situations, i.e. not immediately suggestive of NETs (tests for inherited predisposition to tumors or for a clinical syndrome caused by abnormal hormone secretion).
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Neuroendocrine neoplasm
- Therapeutic area
- Endocrinology
- neuroendocrine neoplasm
- APUDoma
- neuroendocrine neoplasm
- neuroendocrine tumor
- neuroendocrine tumour
- Severity
- Moderate
- Endocrinology
- Oncology
- MONDO ID
- MONDO:0019496
- Parent condition
- MONDO:0002082
Related records
Broader conditions (9)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endocrine gland neoplasm
- Endocrine system disorder
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
Narrower conditions (162)
- Adrenal gland pheochromocytoma
- Ampulla of vater small cell neuroendocrine carcinoma
- Anal canal neuroendocrine neoplasm
- Appendix L-cell glucagon-like peptide-producing neuroendocrine tumor
- Appendix neuroendocrine neoplasm
- Appendix neuroendocrine tumor G1
- Ascending colon neuroendocrine tumor G1
- Atypical carcinoid tumor
- Bartholin gland small cell carcinoma
- Benign adrenal gland pheochromocytoma
- Benign carotid body paraganglioma
- Breast large cell neuroendocrine carcinoma
- Breast neuroendocrine neoplasm
- Bronchial endocrine tumor
- Carcinoid tumor
- Carotid body paraganglioma
- Cecum neuroendocrine tumor G1
- Cervical large cell neuroendocrine carcinoma
- Cervical small cell carcinoma
- Childhood adrenal gland pheochromocytoma
Trials (570)
- "Receptor Radionuclide Therapy With 177Lu-DOTATOC
- [18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
- 11C-Acetate PET/CT Non-FDG-Avid Tumors
- 124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
- 177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs
- 177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.
- 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
- 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
- 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
- 18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
- 18F-AmBF3-TATE PET/CT for Imaging NET Patients
- 18F-DOPA II - PET Imaging Optimization
- 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
- 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies
- 18F-MFBG PET Imaging of the Norepinephrine Transporter in Neural Crest and Neuroendocrine Tumors
- 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Approved drugs (8)
- Avelumab
- Copper oxodotreotide CU-64
- Edotreotide gallium GA-68
- Everolimus
- Lutetium oxodotreotide LU-177
- Sunitinib
- Sunitinib malate
- Telotristat etiprate
Drugs in development (76)
- Adebrelimab Phase 2
- Alectinib Phase 2
- Amino acids Phase 1
- Arginine Phase 1
- Bevacizumab Phase 2
- Cabozantinib Phase 2
- Capecitabine Phase 3
- Carboplatin Phase 1
- Cisplatin Phase 1
- Cyclophosphamide Phase 2
- Dacarbazine Phase 2
- Dalotuzumab Phase 2
- Dordaviprone Phase 2
- Dotamtate PB-212 Phase 1
- Doxorubicin Phase 2
- Edotreotide Phase 3
- Entinostat Phase 2
- Erlotinib Phase 2
- Etoposide Phase 1
- Fludeoxyglucose F 18 Phase 2
Other linked drugs (2)
- Lanreotide acetate
- Platinum